Integrating Clinical Evidence with PBPK Modeling to Assess PPI-Clopidogrel-CYP2C19 Interactions in Chinese ACS Patients.

Drug-drug-gene interaction: CYP2C19 inhibition by pantoprazole or lansoprazole, with no additional effect in poor metabolisers who are already deficient.

This study combines clinical data with physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modelling to quantify the interaction between proton pump inhibitors and clopidogrel according to CYP2C19 genotype. Four hundred and nine Chinese patients with acute coronary syndrome from a prospective study were genotyped for CYP2C19 (alleles 1, 2 and 3) and assessed for platelet reactivity index on clopidogrel, with or without concomitant pantoprazole or lansoprazole. A PBPK model built in PK-Sim, incorporating CYP2C19-specific metabolic pathways, was linked to a pharmacodynamic model of P2Y12 receptor inhibition. In extensive metabolisers, PPI coadministration modestly increased platelet reactivity, whereas no significant change occurred in poor metabolisers; over 90% of predicted Cmax and AUC values fell within 0.5- to 2-fold of clinical data.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

The core observation is pharmacologically sound: you can only phenoconvert what still works, so a PPI penalises extensive metabolisers and leaves poor metabolisers unchanged, already at the floor. Its scope must nonetheless be stated plainly: this is modelling anchored to a biological platelet reactivity endpoint, not clinical events, the effect is described as modest, and the population is exclusively Chinese. The drug-drug-gene framework is the right conceptual tool, but it does not yet replace a strategy trial.

Analysis by Dr Thibaut Benquey